{
    "nctId": "NCT00820872",
    "briefTitle": "Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer",
    "officialTitle": "Phase II Safety Study of Docetaxel and Carboplatin in Combination With Trastuzumab and Lapatinib in Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed primary invasive adenocarcinoma of the breast fulfilling the following criteria:\n\n  * Nonmetastatic disease\n  * Operable and adequately excised\n\n    * Patients with nonresectable deep margin invasion are eligible provided they have had or will receive radiotherapy to the region\n    * Patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumor bed\n  * Node-positive OR -negative and determined eligible to receive adjuvant trastuzumab (Herceptin\u00ae)\n* No positive or suspicious internal mammary nodes by SNS that have not been or will not be irradiated\n* No supraclavicular lymph node involvement (confirmed by fine needle aspiration or biopsy)\n* Over expression and/or amplification of HER2 in the invasive component of the primary tumor, according to one of the following:\n\n  * 3+ over-expression by IHC (\\> 30% of invasive tumor cells)\n  * 2+ or 3+ (in 30% or less neoplastic cells) over-expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification\n  * HER2 gene amplification by FISH/CISH (\\> 6 HER2 gene copies per nucleus, or a FISH ratio \\[HER2 gene copies to chromosome 17 signals\\] of \\> 2.2.)\n\n    * Negative or equivocal overall result (FISH test ratio of \\< 2.2, \\< 6.0 HER2-gene copies per nucleus) and staining scores of 0, 1+, 2+, or 3+ (in 30% or less neoplastic cells) by IHC not allowed\n* Hormone receptor status known (estrogen receptor with or without progesterone receptor)\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Hemoglobin \u2265 10.0 g/dL\n* ANC \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Serum creatinine \u2264 2.0 times upper limit of normal (ULN)\n* AST and ALT \u2264 2.5 times ULN\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Bilirubin \u2264 1.5 times ULN (\u2264 2.0 times ULN if known Gilbert syndrome)\n* Baseline LVEF \u2265 50% measured by ECHO or MUGA scan\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No serious cardiac illness or medical condition including, but not limited to, any of the following:\n\n  * History of documented congestive heart failure (any NYHA class) or systolic dysfunction (LVEF \\< 50%)\n  * High-risk uncontrolled arrhythmias (e.g., ventricular tachycardia, high-grade atrioventricular-block \\[second degree or higher\\], or supraventricular arrhythmias that are not adequately rate-controlled)\n  * Angina pectoris requiring antianginal medication\n  * Clinically significant valvular heart disease\n  * Evidence of transmural infarction on ECG\n  * Poorly controlled hypertension (any reading of systolic BP \\> 180 mm Hg or diastolic BP \\> 100 mm Hg)\n* No other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions or illness\n* None of the following:\n\n  * Ulcerative colitis\n  * Malabsorption syndrome\n  * Any disease significantly affecting gastrointestinal function\n  * Inability to swallow oral medication\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior mediastinal irradiation except internal mammary-node irradiation for the present breast cancer\n* No prior anti-HER2 therapy for any reason\n* No prior biologic or immunotherapy for breast cancer\n* No prior resection of the stomach or small bowel\n* No other concurrent anticancer therapy including chemotherapeutic agents, biologic agents, or radiotherapy\n* No concurrent anticancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the study chair\n* No concurrent CYP3A4 inhibitors or inducers\n* No concurrent epoetin alfa, including darbepoetin alfa\n* No concurrent oprelvekin",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}